Efficacy and safety of anlotinib combined with vinorelbine as second‑line treatment for elderly patients with advanced squamous cell lung carcinoma: A retrospective cohort.

Mol Clin Oncol · 2025 · PMC11706458 · PMID 39776939

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

Median OS was observed at 9.5 months, representing a positive trend compared with existing second-line treatments for this demographic population ( 7 , 16 , 37 ).

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.